Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Items 401–500 of 713
The role of type I interferon signaling in myeloid anti-tumor immunity
Meyer, S. P., Bauer, R., Brüne, B., & Schmid, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1547466 · Cited by 26
Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis
Beasley, E. A., Pessôa-Pereira, D., Scorza, B. M., & Petersen, C. A. (2021) · Animals · doi:10.3390/ani11113206 · Cited by 26
Bhattacharyya, M., Madden, P. J., Henning, N. F. C., Gregory, S., Aïd, M., Martinot, A. J., Barouch, D. H., & Penaloza‐MacMaster, P. (2017) · Immunology · doi:10.1111/imm.12771 · Cited by 23
Dillon, S. M., Guo, K., Austin, G. L., Gianella, S., Engen, P. A., Mutlu, E., Losurdo, J., Swanson, G. R., Chakradeo, P. S., Keshavarzian, A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001863 · Cited by 23
“This lack of correlation may be because of the nonconcurrent kinetics of IFN-I expression and ISG induction [67].”
Crisler, W. J., & Lenz, L. L. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.05.014 · Cited by 25
“Mice pre-treated with blocking antibodies against IFNAR exhibit decreased expression of immune-suppressive PD-L1 and an increased clearance of LCMV that relies on IFNγ responsiveness [27, 28].”
BackgroundActivation of endogenous type I IFN signaling contributes to persistent HCV infection
Li, Y., Li, S., Duan, X., Liu, B., Yang, C., Zeng, P., McGilvray, I. D., & Chen, L. (2014) · Reviews in Medical Virology · doi:10.1002/rmv.1795 · Cited by 22
“Most recently, two independent studies [19,20] reported that blockade of type I IFN signaling may help to cure persistent infection of LCMV clone 13 (LCMV-Cl13) in vivo.”
BackgroundCognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Pulliam, L. (2014) · Current HIV Research · doi:10.2174/1570162x12666140526113544 · Cited by 22
“A mouse model of persistent LCMV infection is accompanied by chronic type 1 IFN signaling, hyperactivation and disease progression [71, 72].”
BackgroundResultGoropevšek, A., Gorenjak, M., Gradišnik, S., Dai, K., Holc, I., Hojs, R., Krajnc, I., Pahor, A., & Avčin, T. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0040 · Cited by 22
IFN-β: A Contentious Player in Host–Pathogen Interaction in Tuberculosis
Sabir, N., Hussain, T. A., Shah, S. Z. A., Zhao, D., & Zhou, X. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122725 · Cited by 24
Baral, S., Roy, R., & Dixit, N. M. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12161 · Cited by 22
“Furthermore, blockade of interferon signaling during chronic LCMV infection of mice has been shown recently to clear the infection.(49,50) Whether a critical time following infection exists within which the start of PR therapy does not exacerbate CTL exhaustion remains to be ascertained.”
BackgroundHIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters
Sugawara, S. K., Thomas, D. L., & Balagopal, A. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0161 · Cited by 22
The ubiquitin-like modifier FAT10 is required for normal IFN-γ production by activated CD8+ T cells
Mah, M. M., Basler, M., & Groettrup, M. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.010 · Cited by 22
Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice
Su, L. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00444-7 · Cited by 22
Measles virus induces persistent infection by autoregulation of viral replication
Doi, T., Kwon, H.-J., Honda, T., Sato, H., Yoneda, M., & Kai, C. (2016) · Scientific Reports · doi:10.1038/srep37163 · Cited by 22
Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion
Li, M. M. H., Bozzacco, L., Hoffmann, H.-H., Breton, G., Loschko, J., Xiao, J., Monette, S., Rice, C. M., & MacDonald, M. R. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160303 · Cited by 25
“Neutralization of type I IFN signaling during persistent lymphocytic choriomeningitis virus (LCMV) infection reduces immune system activation, restores lymphoid architecture, and allows for viral clearance (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundIshihara, R., Watanabe, R., Shiomi, M., Fujita, Y., Katsushima, M., Fukumoto, K., Yamada, S., & Hashimoto, M. (2025) · Biomolecules · doi:10.3390/biom15111586 · Cited by 24
Durand, A., Bonilla, N., Level, T., Ginestet, Z., Lombès, A., Guichard, V., Germain, M., Jacques, S., Letourneur, F., Cruzeiro, M. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45984-8 · Cited by 21
Fc gamma receptor IIa suppresses type I and III interferon production by human myeloid immune cells
Newling, M., Hoepel, W., Vogelpoel, L. T. C., Heineke, M. H., van Burgsteden, J. A., Taanman-Kueter, E. W., Eggink, D., Kuijpers, T. W., Beaumont, T., van Egmond, M., et al. (2018) · European Journal of Immunology · doi:10.1002/eji.201847615 · Cited by 21
Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10
Llópiz, D., Ruiz, M., Silva, L., & Sarobe, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01923 · Cited by 25
“IL-10 and type I IFN production have been linked as regulatory mechanisms, and blockade of IFN signal leads to a diminished IL-10 expression (81, 82).”
BackgroundResultLiu, D., Gibb, D. R., Escamilla‐Rivera, V., Liu, J., Santhanakrishnan, M., Shi, Z., Xu, L., Eisenbarth, S. C., & Hendrickson, J. E. (2019) · Transfusion · doi:10.1111/trf.15482 · Cited by 22
Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti- Toxoplasma Immunity
Hu, Z., Wu, D., Lu, J., Zhang, Y., Yu, S.-M., Xie, Y., Li, H., Yang, J., Lai, D., Zeng, K., et al. (2022) · mBio · doi:10.1128/mbio.02361-22 · Cited by 22
The added value of type I interferons to cytotoxic treatments of cancer
Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 21
IFNα Subtypes in HIV Infection and Immunity
Karakoese, Z., Ingola, M., Sitek, B., Dittmer, U., & Sutter, K. (2024) · Viruses · doi:10.3390/v16030364 · Cited by 20
“Similar observations were also reported from chronic infections with Lymphocytic Choriomeningitis Virus (LCMV) in mice, in which blockade of IFNAR1 resulted in the control of persistent LCMV infection [88,89].”
ResultGreene, T. T., Jo, Y., Chiale, C., Macal, M., Fang, Z., Khatri, F. S., Codrington, A. L., Kazane, K. R., Akbulut, E., Swaminathan, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56603-5 · Cited by 22
Scala, M. D., Otano, I., Gil-Fariña, I., Vanrell, L., Hommel, M., Olagüe, C., Vales, Á., Galarraga, M., Guembe, L., Ortíz-de-Solórzano, C., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01030-16 · Cited by 20
Olferiev, M., Jacek, E., Kirou, K. A., & Crow, M. K. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.08.018 · Cited by 20
Zhang, L., Zhang, Z., Wu, X., Jiang, Y., Fu, Y., & Shang, H. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1294-5 · Cited by 24
HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells
Veenhuis, R. T., Freeman, Z. T., Korleski, J., Cohen, L. K., Massaccesi, G., Tomasi, A. G., Boesch, A. W., Ackerman, M. E., Margolick, J. B., Blankson, J. N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95375 · Cited by 20
Gill, U. S., & Kennedy, P. T. F. (2018) · Journal of Viral Hepatitis · doi:10.1111/jvh.13040 · Cited by 21
Pfaff, F., Hägglund, S., Zoli, M., Blaise‐Boisseau, S., Laloy, E., Koethe, S., Zühlke, D., Riedel, K., Zientara, S., Bakkali‐Kassimi, L., et al. (2019) · Viruses · doi:10.3390/v11010053 · Cited by 21
“The blockade of IFNR by antibodies abolished the expression of IL-10 and PD-L1, two immunosuppressive T-cell exhaustion factors expressed by dendritic cells, and ultimately led to clearance of persistent LCMV infection by activation of IFN-γ expressing CD4+ T cells [52].”
BackgroundInfluentialFu, B., Wang, D., Shen, X., Guo, C., Liu, Y., Ye, Y., Sun, R., Li, J., Tian, Z., & Wei, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591269 · Cited by 21
“IFNa has been reported to lead to the production of immunosuppressive molecules in models of Simian Immunodeficiency Virus (SIV) (39) and LCMV infection (11, 12).”
BackgroundPulliam, L., Calosing, C., Sun, B., Grünfeld, C., & Rempel, H. C. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0152 · Cited by 23
Hoffman, K. W., Sachs, D. M., Bardina, S. V., Michlmayr, D., Rodriguez, C. A., Sum, J., Foster, G. A., Krysztof, D. E., Stramer, S. L., & Lim, J. K. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw179 · Cited by 20
“much initial inflammation may negatively impact how these adaptive T-cell responses are shaped, as appears to be the case for WNV infection in our cohort [23, 24].”
BackgroundTumor-necrosis factor is a master of T cell exhaustion
Baxter, A. E., & Kaufmann, D. (2016) · Nature Immunology · doi:10.1038/ni.3436 · Cited by 20
Slow viral propagation during initial phase of infection leads to viral persistence in mice
Xu, H. C., Wang, R., Shinde, P. V., Walotka, L., Huang, A., Poschmann, G., Huang, J., Liu, W. Y., Stühler, K., Schaal, H., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02028-x · Cited by 20
Bénard, A., Hansen, F. J., Uhle, F., Klösch, B., Czubayko, F., Mittelstädt, A., Jacobsen, A., David, P., Podolska, M. J., Anthuber, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140630 · Cited by 22
“Whereas type I interferons are critical for early immune responses against acute lymphocytic choriomeningitis virus (LCMV) infections, they contribute to the altered immunity during chronic LCMV infections (41, 42).”
BackgroundHeterogeneity and functions of the 13 IFN‐α subtypes – lucky for some?
Moreau, T., Bondet, V., Rodero, M. P., & Duffy, D. (2023) · European Journal of Immunology · doi:10.1002/eji.202250307 · Cited by 19
Choi, S.-H., Lee, J., Kim, S., Lee, Y. W., Kim, G.-C., Hong, S.-M., An, S.-H., Noh, H., Kim, K. E., On, D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2023.104932 · Cited by 19
Two separate mechanisms of enforced viral replication balance innate and adaptive immune activation
Shaabani, N., Khairnar, V., Duhan, V., Zhou, F., Ferrer-Tur, R., Häussinger, D., Recher, M., Tumanov, A. V., Hardt, C., Pinschewer, D. D., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.10.004 · Cited by 19
Manipulating the Interferon Signaling Pathway: Implications for HIV Infection
Nganou‐Makamdop, K., & Douek, D. C. (2019) · Virologica Sinica · doi:10.1007/s12250-019-00085-5 · Cited by 20
Roles of IκB kinase ε in the innate immune defense and beyond
Zhang, J., Tian, M., Xia, Z., & Feng, P. (2016) · Virologica Sinica · doi:10.1007/s12250-016-3898-y · Cited by 20
“The dramatically reduced γHV68 latent infection in IKKε-deficient mice is reminiscent of the observation that blockade of type I IFNs reduced LCMV latent infection in mice (Teijaro et al., 2013; Wilson et al., 2013) .”
BackgroundCitro, A., Scrivo, R., Martini, H., Martire, C., Marzio, P. D., Vestri, A. R., Sidney, J., Sette, A., Barnaba, V., & Valesini, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128607 · Cited by 19
“Recently, a strict relationship between sustained type I IFN (IFN-I) signaling and PD-1 overexpression on T cells, resulting in the establishment of a low level of CIA and decreased effector functions by virus-specific T cells, has been demonstrated in the mouse model of persistent lymphocytic choriomeningitis virus i…”
BackgroundAbdullah, L., Emiliani, F. E., Vaidya, C., Stuart, H., Musial, S. C., Kolling, F., Obar, J. J., Rosato, P. C., Ackerman, M. E., Li, S., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.001 · Cited by 22
The PD-1/PD-L1 pathway and Epstein–Barr virus
Wang, H., Zhang, N., Xu, R., Ji, C., Wei, Y., Liu, Z., & Mi, Q. S. (2025) · European journal of medical research · doi:10.1186/s40001-025-02694-1 · Cited by 20
“Studies have shown that suppression or deficiency of the type I IFN signaling pathway leads to reduced PD-L1 expression during chronic LCMV infection, despite increased viral replication [89, 90].”
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca, L. E., & Hafler, D. A. (2017) · Immunological Reviews · doi:10.1111/imr.12529 · Cited by 18
Drivers and regulators of humoral innate immune responses to infection and cancer
Kumar, D., Romero, Y., Schuck, K. N., Smalley, H., Subedi, B., & Fleming, S. D. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.03.005 · Cited by 20
“Blocking type I interferon receptor in LCMV infections initially increased viral titers but ultimately allowed for clearance of the persistent infection (Wilson et al., 2013).”
BackgroundSARS‐CoV‐2, HIV, and HPV: Convergent evolution of selective regulation of cGAS–STING signaling
Shen, S., Rui, Y., Wang, Y., Su, J., & Yu, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28220 · Cited by 18
Enzymolysis-based RNA pull-down identifies YTHDC2 as an inhibitor of antiviral innate response
Zhu, J., Liu, S., Fang, J., Cui, Z., Wang, B., Wang, Y., Liu, L., Wang, Q., & Cao, X. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113192 · Cited by 17
Nef, the shuttling molecular adaptor of HIV, influences the cytokine network
Percario, Z. A., Ali, M., Mangino, G., & Affabris, E. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.010 · Cited by 20
“Curiously, blockade of type I IFN signaling helps resolve persistent infection by LCMV in a mouse model [166,167] suggesting that impeding interferon signaling in”
BackgroundMoyano, A. L., Steplowski, J., Wang, H., Son, K., Rapolti, D. I., Marshall, J. N., Elackattu, V., Marshall, M. S., Hebert, A., Reiter, C. R., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.008 · Cited by 17
Mechanisms of Immune Modulation by Radiation
Spina, C. S., & Drake, C. G. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.02.001 · Cited by 18
Xu, L., Fan, X., Zhao, Q.-Z., Zhang, Z.-X., Chen, K., Yi-bao, N., Zhang, Q.-Y., Zou, X., Zhu, Y., Cui, L., et al. (2017) · Viral Immunology · doi:10.1089/vim.2017.0010 · Cited by 17
“The expression of suppressive factors is tightly linked to viral burden, suggesting the presence of an immunologic sensory system that continually measures the magnitude and duration of viral replication and then dynamically modulates the balance between antiviral immunity and immune exhaustion (30).”
The Janus Face of Follicular T Helper Cells in Chronic Viral Infections
Greczmiel, U., & Oxenius, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01162 · Cited by 19
Transcription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 17
“Similarly, overactivation of type I interferon signaling can be blocked by inhibiting signaling through IFNAR1 and IFNAR2 upstream of STATs [51,204].”
Bullock, C. B., Wang, L., Ware, B. C., Wagoner, N., Ohara, R. A., Liu, T., Desai, P., Peters, B., MURPHY, K. M. M., Handley, S. A., et al. (2024) · mBio · doi:10.1128/mbio.02930-24 · Cited by 17
“Alternatively, anti-IFNAR1 mAb treatment may help correct a functionally overactive innate immune response, such as that occurring during the chronic stage of LCMV clone 13 infection, where the IFNAR1 blockade improved CD8 + T-cell viral control (53, 54).”
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C
Mondelli, M. U. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.026 · Cited by 16
Antiviral Effect of Interferon Lambda Against Lymphocytic Choriomeningitis Virus
Lukáčiková, Ľ., Ovečková, I., Betáková, T., Laposova, K., Polčicová, K., Pastoreková, S., Pastorek, J., & Tomášková, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0083 · Cited by 16
Negrotto, S., Mena, H. A., Ure, A. E., de Giusti, C. J., Bollati‐Fogolín, M., Vermeulen, E. M., Schattner, M. A., & Gomez, R. M. (2015) · Journal of Virology · doi:10.1128/jvi.01014-15 · Cited by 16
“In mice intravenously infected with a high dose (2 3 10(6) PFU) of LCMV, virus persistence is controlled by blocking IFN-I signaling (37, 38).”
BackgroundJiang, R., Han, B., Song, M., Xue, B., Zhang, Y., Ding, Y., Jin, C., Zhu, J., Liu, J., Nie, Q., et al. (2020) · Journal of Inflammation · doi:10.1186/s12950-020-00249-1 · Cited by 16
IFNAR1 signaling in NK cells promotes persistent virus infection
Huang, Z., Kang, S. G., Li, Y., Žák, J., Shaabani, N., Deng, K., Shepherd, J., Bhargava, R., Teijaro, J. R., & Xiao, C. (2021) · Science Advances · doi:10.1126/sciadv.abb8087 · Cited by 17
Johnson, E. L., Swieboda, D., Olivier, A., Enninga, E. A. L., & Chakraborty, R. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009860 · Cited by 18
“Type I IFN, through the IFN-α/β receptor (IFNAR), induce a multitude of IFN-stimulated genes (ISGs) that can block viral replication and alert the immune system in response to virus [33, 42, 43].”
BackgroundSrivastava, S., Koch, L. K., & Campbell, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401039 · Cited by 17
“extent and duration of their expression during acute and chronic infection, respectively (15, 16).”
BackgroundToo Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy
Reading, J. L., & Quezada, S. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.12.004 · Cited by 16
“Emerging evidence of the immunoregulatory effects of IFN signaling presented here and elsewhere (Teijaro et al., 2013; Wilson et al., 2013) sheds light on these findings.”
BackgroundManske, K., Kallin, N., König, V., Schneider, A., Kurz, S., Bosch, M., Welz, M., Cheng, R., Bengsch, B., Steiger, K., et al. (2018) · Hepatology · doi:10.1002/hep.30080 · Cited by 16
“This includes infection with different strains of LCMV, in which clone WE is rapidly cleared and clone-13 persists due to interferon-induced impairment of immunity and induction of dysfunctional antiviral T-cells through high antigen levels.(29-31) In addition, the mode of viral gene delivery to hepatocytes determines…”
BackgroundStudstill, C. J., & Hahm, B. (2021) · Viruses · doi:10.3390/v13101951 · Cited by 16
“Similarly, IFN-I stimulated genes are upregulated and remain elevated in spleen tissue [97].”
BackgroundTarbell, K. V., & Egen, J. G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir1017-400r · Cited by 16
Kawashima, K., Isogawa, M., Hamada‐Tsutsumi, S., Baudi, I., Saito, S., Nakajima, A., & Tanaka, Y. (2018) · Journal of Virology · doi:10.1128/jvi.01099-18 · Cited by 15
“lymphocytic choriomeningitis virus (LCMV) (35, 36).”
ResultRaju, S., Verbaro, D., & Egawa, T. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.092 · Cited by 15
“As shown previously (Teijaro et al., 2013; Wilson et al., 2013), anti-IFNAR alone on day −1 prior to infection accelerated resolution of viremia compared to control (Figure 4D).”
BackgroundInfluentialSerum levels of type I interferon (IFN-I) is associated with the severity of COVID-19
Sun, Y., Wang, G., Wang, R., Ren, L., Yuan, Z., Liu, Y., Wu, Y., Chen, R., Chen, Y., & Diao, B. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001694 · Cited by 15
IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling
Otero, D. C., Fares-Frederickson, N. J., Xiao, M., Baker, D. P., & David, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403181 · Cited by 15
“Interestingly, by simply blocking IFN signaling in LCMV Cl13– infected mice, one can prevent or revert T cell exhaustion and induce clearance of the virus (29, 30).”
BackgroundMbanwi, A. N., Wang, C., Geddes, K., Philpott, D. J., & Watts, T. H. (2016) · European Journal of Immunology · doi:10.1002/eji.201646666 · Cited by 15
Dagenais-Lussier, X., Loucif, H., Cadorel, H., Blumberger, J., Isnard, S., Bego, M. G., Cohen, É. A., Routy, J., van Grevenynghe, J., & for the Montreal Primary Infection Study Group (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008060 · Cited by 15
Oldstone, M. B. A. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu501 · Cited by 16
“Finally, we are evaluating different strategies used by LCMV Cl 13 compared to LCMVArmstrong (ARM) for signaling the IFN-1α,β receptor (Figure 1).”
BackgroundInfluentialSystemic Factors Mediate Reversible Age-Associated Brain Dysfunction
Mendelsohn, A. R., & Larrick, J. W. (2014) · Rejuvenation Research · doi:10.1089/rej.2014.1643 · Cited by 16
The curious case of type I interferon signaling in cancer
Chhipa, A. S., Boscaro, V., Gallicchio, M., & Patel, S. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189204 · Cited by 15
T cell aging and exhaustion: Mechanisms and clinical implications
Zhang, W., Kong, D., Zhang, X., Hu, L., Nian, Y., & Shen, Z. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110486 · Cited by 14
Lutkewitte, A. J., Singer, J., Shew, T. M., Martino, M. R., Hall, A. M., He, M., & Finck, B. N. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101204 · Cited by 15
“During each ASO treatment, mice were also given intraperitoneal (IP) injections of IgG control (BioCell InVivoIMAb, #BE0083, clone MOPC-21) or a monoclonal neutralizing antibody targeting interferon alpha/beta receptor 1 (IFNAR-1) (BioCell InVivoIMAb, #BE0241, clone MAR1-5A3) [23].”
MethodAutoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage
Kasmani, M. Y., Ciecko, A. E., Brown, A. K., Петрова, Г. В., Gorski, J., Chen, Y., & Cui, W. (2022) · Life Science Alliance · doi:10.26508/lsa.202201503 · Cited by 15
“In models of chronic viral infection, blocking type I IFN signaling promotes viral control, likely due to reduced CD8 T cell exhaustion (Teijaro et al, 2013; Wilson et al, 2013; Wu et al, 2016); similar mechanisms may therefore regulate the development of exhausted CD8 T cells in T1D.”
BackgroundQin, Q., Shwetank, Frost, E. L., Maru, S. Y., & Lukacher, A. E. (2016) · Journal of Virology · doi:10.1128/jvi.00199-16 · Cited by 15
“IFN-I receptor blockade has been reported to reverse CD8 T cell exhaustion and to control chronic LCMV infection (67, 75).”
BackgroundVerhoeven, D. E., George, M. D., Hu, W. K., Dang, A. T., Smit‐McBride, Z., Reay, E., Macal, M., Fenton, A. N., Sankaran‐Walters, S., & Dandekar, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302415 · Cited by 15
“sistent but limited antiviral responses (15, 16).”
Interferon Control of Neurotropic Viral Infections
Milora, K. A., & Rall, G. F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.07.005 · Cited by 13
Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling
Zoellner, N., Coesfeld, N., Vos, F. H. D., Denter, J., Xu, H. C., Zimmer, E., Knebel, B., Al‐Hasani, H., Moßner, S., Lang, P. A., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.947169 · Cited by 13
“However, a prolonged IFN signaling can be observed during chronic LCMV viral infection, this leads to up-regulation of PD-L1 and IL-10 on dendritic cells and macrophages, thereby contributing to the T-cell exhaustion (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundVaranasi, V., Khan, A. A., & Chervonsky, A. V. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401750111 · Cited by 13
Govender, U., Corre, B., Bourdache, Y., Pellegrini, S., & Michel, F. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a0416-187rr · Cited by 14
“IFN-a/b activity has also been associated with an immunosuppressive program whose hallmarks are inhibition of proinflammatory cytokines, expression of inhibitory receptors and anti-inflammatory cytokines, and decreased T cell responses [1, 2, 5].”
BackgroundDelaloye, J., Filali-Mouhim, A., Cameron, M. J., Haddad, E. K., Harari, A., Goulet, J.-P., Gómez, C. E., Perdiguero, B., Estéban, M., Pantaleo, G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.03061-14 · Cited by 14
“However, chronic type I IFN signaling has also been associated with disease progression in chronic viral infections caused by lymphocytic choriomeningitis virus (LCMV), simian immunodeficiency virus (SIV), or hepatitis C virus (HCV).”
BackgroundJofra, T., Galvani, G., Kuka, M., Fonte, R., Mfarrej, B. G., Iannacone, M., Salek‐Ardakani, S., Battaglia, M., & Fousteri, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00811 · Cited by 13
“Type I IFNs not only promote innate and adaptive immune activation but are also responsible for the exhaustion of T cells (34, 35).”
Arenaviridae exoribonuclease presents genomic RNA edition capacityPreprint
Yekwa, E. L., Aphibanthammakit, C., Carnec, X., Coutard, B., Picard, C., Canard, B., Baize, S., & Ferrón, F. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/541698 · Cited by 13
“Despite its public health significance, and recent major contributions [21–25], Arenaviridae biology is still poorly understood.”
BackgroundLlópiz, D., Ruiz, M., Silva, L., Repáraz, D., Aparicio, B., Egea, J., Lasarte, J. J., Redín, E., Calvo, A., Angel, M., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.022 · Cited by 13
Svanberg, C., Nyström, S. N., Govender, M., Bhattacharya, P., Che, K. F., Ellegård, R., Shankar, E. M., & Larsson, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790276 · Cited by 13
“It is becoming clear from several studies, that for type I IFNs, the magnitude and timing of expression are essential for the outcome of the infection and quality of the immune responses (40, 87, 89).”
BackgroundMutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice
Qin, Z., Liu, H., Sheng, Q., Dan, J., Wu, X., Li, H., Wang, L., Zhang, S., Yuan, C., Yuan, H., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250211 · Cited by 12
Papatriantafyllou, M. (2013) · Nature reviews. Immunology · doi:10.1038/nri3461 · Cited by 12
Wang, F., Wang, Y. Y., Li, J., You, X., Qiu, X. H., Wang, Y. N., & GAO, F. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105636 · Cited by 12
“immune environment to enable control of infection [17], indicating that IFN-I signaling might contribute to DCs’”
BackgroundDifference of two new LCMV strains in lethality and viral genome load in tissues
Takagi, T., Ohsawa, M., Yamanaka, H., Matsuda, N., Sato, H., & Ohsawa, K. (2017) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.16-0097 · Cited by 12
“another study demonstrates that interfering with chronic iFn-i signaling during persistent infection redirects the immune environment to enable control of infection [25].”
BackgroundNi, G., Liao, Z., Chen, S., Wang, T., Yuan, J., Pan, X., Mounsey, K. E., Walton, S. F., Liu, X., & Wei, M. Q. (2017) · BMC Immunology · doi:10.1186/s12865-017-0224-x · Cited by 12
Mehrotra, A., D’Angelo, J. A., Romney-Vanterpool, A., Chu, T., Bertoletti, A., Janssen, H. L. A., & Gehring, A. J. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa064 · Cited by 12
Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection
Mu, W., Kedia, N., & Zhen, A. (2025) · Viruses · doi:10.3390/v17060774 · Cited by 11
“Persistent type I IFN also promotes the release of inflammatory cytokines, such as IL-10 and TGF-β , which are known to suppress T cell activity and reinforce an immunosuppressive environment [23,92–94].”
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 12
“Indeed, blocking type I IFNs has been shown to improve antiviral and antitumor immune responses in both chronic lymphocytic choriomeningitis virus infection and tumors [279, 302, 303].”
Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo
Abdel‐Mohsen, M., Deng, X., Danesh, A., Liegler, T. J., Jacobs, E. S., Rauch, A., Ledergerber, B., Norris, P. J., Günthard, H. F., Wong, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109220 · Cited by 11
“This paradox is mirrored in recent studies of LCMV infection suggesting that IFN-a is associated with both beneficial and detrimental disease outcomes, and disease progression is governed by the overall balance between the various, diverse effects of type I interferon [12,13].”
Type I interferon signaling promotes radioresistance in head and neck cancer
Zenga, J., Awan, M. J., Frei, A. C., Massey, B. L., Bruening, J., Shukla, M., Sharma, G. P., Shreenivas, A. V., Wong, S. J., Zimmermann, M. T., et al. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2104 · Cited by 11
“In the chronic phase of viral infection, type I IFNs lead to increased expression of immunoregulatory factors, such as IL6, IL10, and PD-L1 (27,28).”
Maturation inside and outside bone marrow dendritic cells (BMDCs) modulated by interferon-α (IFN-α)
Song, Q., Meng, Y., Wang, Y., Li, M., Zhang, J., Xin, S., Wang, L., & Shan, F. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.09.011 · Cited by 11
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.